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Abstract
Spinocerebellar ataxia type 13 (SCA13) is an autosomal dominantly inherited neurodegen-
erative disorder of the cerebellum caused by mutations in the voltage gated potassium
channel KCNC3. To identify novel pathogenic SCA13 mutations in KCNC3 and to gain in-
sights into the disease prevalence in the Netherlands, we sequenced the entire coding re-
gion of KCNC3 in 848 Dutch cerebellar ataxia patients with familial or sporadic origin. We
evaluated the pathogenicity of the identified variants by co-segregation analysis and in sil-
ico prediction followed by biochemical and electrophysiological studies. We identified 19
variants in KCNC3 including 2 non-coding, 11 missense and 6 synonymous variants. Two
missense variants did not co-segregate with the disease and were excluded as potentially
disease-causing mutations. We also identified the previously reported p.R420H and p.
R423H mutations in our cohort. Of the remaining 7 missense variants, functional analysis
revealed that 2 missense variants shifted Kv3.3 channel activation to more negative volt-
ages. These variations were associated with early disease onset and mild intellectual dis-
ability. Additionally, one other missense variant shifted channel activation to more positive
voltages and was associated with spastic ataxic gait. Whereas, the remaining missense
variants did not change any of the channel characteristics. Of these three functional vari-
ants, only one variant was in silico predicted to be damaging and segregated with disease.
The other two variants were in silico predicted to be benign and co-segregation analysis
was not optimal or could only be partially confirmed. Therefore, we conclude that we have
identified at least one novel pathogenic mutation in KCNC3 that cause SCA13 and two addi-
tionally potential SCA13 mutations. This leads to an estimate of SCA13 prevalence in the
Netherlands to be between 0.6% and 1.3%.
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Introduction
Spinocerebellar ataxia type 13 (SCA13) is an autosomal dominantly inherited neurodegenera-
tive disorder characterized by atrophy of the cerebellum, especially the vermis, leading to a cere-
bellar syndrome with dysarthria and nystagmus. It is sometimes accompanied by pyramidal
signs, epilepsy, auditory deficits, and mild intellectual disability [1–5]. Disease onset varies from
early childhood, with delayed motor and cognitive skills acquisition, to late-onset, but the course
is always very slowly progressive. The disease is caused by missense mutations in the KCNC3
gene, which encodes the voltage-gated potassium channel subfamily C member 3, Kv3.3 [2,6].
The physiological role of Kv3.3 channels in the cerebellum is well known. Purkinje cells (PC)
express Kv3.3 in both soma and dendrites [7–10], and plays a crucial role in the PC spikelets re-
polarization and shaping of the complex spike [11,12]. Kv3.3 forms tetrameric heterocomplexes
with other Kv3 subunits to form a functional channel [13,14] and this has been implicated in
A-type potassium currents that enable neurons to fire action potentials at high-frequencies [15].
So far, only three disease-causing mutations have been reported in KCNC3: p.R420H,
p.R423H and p.F448L [2,6]. Functional analysis showed that p.R420H and p.R423H reduce
Kv3.3 current amplitude and cell surface expression by a dominant negative mechanism,
whereas p.F448L alters the voltage-dependence of activation [2,6,16,17]. The pathological con-
sequences of these channel alterations were validated in transgenic zebra fish and cellular mod-
els, showing deficits in locomotor control caused by suppression of the fast-spiking motor
neurons excitability, defective axon pathfinding, and decreased current amplitude in the zebra-
fish, and impaired dendrite development and cell death in the mouse [14,18–20].
SCA13 disease prevalence among the dominant ataxias has been estimated approximately
1.5% in Europe, which is comparable to the prevalence of other non-polyQ SCA types such as
SCA11, 19, 23, and 28 [21–25]. In American pedigrees of mixed ethnicity, the prevalence is es-
timated to be less than 1% [26]. SCA13 has not yet been reported in China [27,28].
In this study, we aimed to identify novel mutations, to get more insight in genotype-
phenotype correlations and to come up with an updated assessment of SCA13 disease preva-
lence in the Netherlands.
Materials and Methods
Subjects and KCNC3mutation screening
Two Dutch cohorts were screened: one with 316 cerebellar ataxia patients from the Department
of Genetics, University of Groningen (UMCG) and the other with 532 cerebellar ataxia patients
from the Department of Medical Genetics, University Medical Center Utrecht (UMCU), the
complete coding region and the exon-intron boundaries of KCNC3 (HGNC: 6235) were exam-
ined through Sanger sequencing using the ABI3700 system (Applied Biosystems). Both diagnos-
tic cohorts contained a mixture of unknown familial and sporadic cases. Only DNA samples
were included from patients in whom testing for SCA1–3, 6, 7, 12–14, and 17 had been re-
quested. This study did not require ethical approval since all extended DNA analyses were per-
formed by accredited diagnostic DNA laboratories. The additional tests were thus performed in
line with the original diagnostic request and no ethical committee approval was necessary.
Moreover, all these patients had given permission for their DNA to be used in (anonymous)
studies to help develop or improve diagnostics. However, upon the identification of potential
disease causing variants, the research code was opened by the staff members of the diagnostic
laboratories to reveal the identity of the corresponding case. Additionally, the consulting genetic
clinician or treating neurologist was requested to recruit available family members and they also
communicated the final outcomes of the test with the patient and its relatives.
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The primers used for KCNC3 sequencing are listed in S1 Table. The DNA sequences were
analyzed using Mutation Surveyor software (Softgenetics). All the genetic variants identified
were analyzed in silico with Alamut software (Interactive Biosoftware) to obtain clues
about pathogenicity.
Molecular biology
Human KCNC3 cDNA (AF055989.1) in pHELP vector was kindly provided by Gianrico Farru-
gia (Mayo Clinic, Rochester, Minnesota, USA). The complete KCNC3 cDNA was amplified
using primers (S2 Table) flanked by EcoRI and KpnI restriction sides on 3’and 5’ends, respec-
tively, to facilitate subcloning into pEGFP-C1 (Clontech). Mutations were introduced by site-
directed mutagenesis PCR using specific primer pairs (S2 Table). The constructs were checked
for correctness by direct sequencing.
Cell culture and transfection
HeLa cells were grown in Dulbecco’s Modified Eagle’s Medium (Invitrogen) supplemented with
10% fetal bovine serum (Invitrogen) and 1% penicillin-streptomycin (Gibco). Chinese hamster
ovary (CHO-K1) were maintained in Dulbecco’s Modified Eagle Medium: Nutrient Mixture
F-12 medium (Gibco) supplemented by 10% fetal bovine serum and 1% penicillin-streptomy-
cin. All cultures were kept at 37°C incubator with 5% CO2. For immunocytochemistry and
Western blot, HeLa cells were seeded onto glass coverslips and transfected with 0.5 μg pEGFP-
KCNC3WT or mutants, or onto 6 wells/plate and transfected with 2 μg of pEGFP-KCNC3WT
or mutants, respectively, with polyethylenimine (Polysciences). For electrophysiology, CHO-K1
cells were seeded onto glass coverslips and transfected with 0.5 μg of pEGFP-KCNC3WT or
mutants with Genius (Westburg), following the manufacturer’s instructions. No differences in
channel activity were observed between Kv3.3 and EGFP-tagged Kv3.3.
Immunocytochemistry andWestern blot
Immunofluorescense and Western blot were performed as previously described [29]. Briefly,
transfected HeLa cells were fixed with 4% Paraformaldehide for 15 min, blocked and permeabi-
lized with 0.1% Trition X-100, 5% normal goat serum in PBS (phosphate buffered saline) for
30 min at room temperature. The antibodies used in immuncytochemistry were anti-Calnexin
(1:200; Santa Cruz), anti-Golgin 97 (1:200; Santa Cruz) and a secondary Cy3-conjugated goat
anti-rabbit (1:500; Jackson ImmunoResearch). Coverslips were mounted in Vectashield
mounting medium with Dapi (Vector Labs). Images were acquired using a Leica DMI 6000 In-
verted microscope (Leica Microsystems GmbH, Germany) and processed using ImageJ soft-
ware (National Institutes of Health, Bethesda, MA, USA). For Western blot, transfected HeLa
cells were lysated with 2% SDS (sodium dodecyl sulfate) in PBS with protease inhibitors
(Roche) and analyzed by 6% SDS-PAGE. Anti-Kv3.3 (1:500; Alomone) and anti-actin (1:5000;
MP Biochemicals) antibodies were used.
Electrophysiology
Patch clamp experiments were performed as previously described (Duarri et al., 2012). In
short, potassium currents were recorded in the whole-cell configuration in CHO-K1 cells
transfected either with wild type or mutant pEGFP-KCNC3 constructs. Current amplitudes
were measured by pulsing from a holding potential of-90 mV to voltages ranging from-70 to
+70 mV in 10 mV depolarizing steps (800 ms). To characterize the steady-state properties of
activation, conductance values were calculated from peak current amplitudes and normalized
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to the maximum value obtained in the experiment. Normalized conductance values were plot-
ted versus test voltage and data were fitted with a single Boltzmann function to provide values
for the midpoint voltage (V1/2) and slope factor. Clampfit 8.2 (Axon Instruments) and Sigma-
Plot 11.0 (Systat Software Inc.) were used and statistical significance was determined using a
two-sample Student’s t test. Average values are expressed as mean ± SEM.
Results
Identification of novel KCNC3 variants
The entire coding region of KCNC3 was successfully sequenced in 848 cases and we identified
19 genomic variations, including 2 non-coding, 11 missense, and 6 synonymous variants
(Table 1). Two of the missense variants, p.R420H and p.R423H, have previously been reported
to be pathogenic as these mutations cause aberrant Kv3.3 channel functioning [2,6,16,18]. The
p.R420H mutation was found in four affected members from three different families. The age of
onset varied from 25–50 years of age. In the first p.R420H family, two affected cousins suffered
from a slowly progressive cerebellar syndrome. In the second p.R420H family, a woman mani-
fested a rather pure cerebellar syndrome but with normal cognitive function. Her brother also
showed pyramidal signs with high tone in the legs and Babinski reflexes in addition to his cere-
bellar ataxia. The fourth p.R420H patient appeared to be sporadic. To investigate the possibility
that the three p.R420H families might be related, haplotyping was performed using markers sur-
rounding KCNC3, but no common haplotype was detected (data not shown). The p.R423H mu-
tation was only seen once and turned out to be a de novo mutation. This female patient suffered
from congenital ataxia, with a spastic ataxic gait, and mild intellectual disability. The age of
onset was ~2 years and she exhibited slow motor development that stabilized during adulthood.
From the other 17 genomic coding variants found, 12 have not yet been reported (see
Table 1 and partly in S3 Table), including 8 missense and 4 synonymous variants. These vari-
ants were not present in the genetic database Exome Variant Server (EVS, 8500 European
exomes) or Genome of the Netherlands (GoNL,500 Dutch exomes). Two missense variants,
p.Q41H and p.D63G, were excluded as potentially disease-causing, as p.Q41H was also ob-
served in unaffected relatives of the index cases and p.D63G was detected in the homozygous
state and glycine was found at position 63 in the phyla. In contrast, p.D477N was only detected
twice (2/8500) in the EVS database, and therefore remained of interest.
To follow-up on our findings, we assessed the pathogenicity of the remaining missense vari-
ants using the in silico prediction program Alamut, and compared the outcomes to the predic-
tion outcome of the known mutations. Not surprisingly, the known missense mutations
p.R420H and p.R423H were scored as ‘damaging’ by all the prediction programs (SIFT, Poly-
Phen2, Mutationtaster, and Align GVGD) used by Alamut (see Table 1), while another known
mutation, p.F448L, was predicted to be ‘benign’ in silico (data not shown) but had previously
proven functionally to be pathogenic [6]. For the novel missense variants, only p.V535M was
predicted to be damaging by all programs, and this mutation co-segregated with the disease in
two affected family members, both suffering from early-onset (age 2–3 years), slowly progres-
sive, cerebellar ataxia with mild intellectual disability.
The variants p.D129N, p.G643S, and p.P645R were predicted to be damaging by two pro-
grams (Table 1). The variants p.D477N and p.D746N were predicted to be damaging by one
program, while p.S591G was predicted to be benign by all programs (Table 1). Consequently,
all the new variants were defined as unclassified variants. These variants were detected in ap-
parently sporadic cases, with the exception of p.S591G, which was familial in 3 out of the 5
identified cases. In fact, two cases turned out to be directly related (second family). In the first
family, two sibs suffered from a slowly progressive cerebellar ataxia with spastic ataxic gait that
KCNC3Mutational Spectrum in Dutch Ataxia Cases
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presented at a young age (~10–15 years). Their father, who also carried the p.S591G variation,
did not demonstrate any clinical symptoms at age 65, which may be indicative for a potentially
very late disease onset or for non-penetrance. Additionally, this could also imply that this vari-
ant is not the disease causing variant in this family. However, in the second family, the p.S591G
variation was detected in two affected brothers (treated as unrelated referrals in each of the ge-
netic centers), with a late age-of-onset (55 and>70 years). One brother suffered from a slowly
progressive cerebellar syndrome with no additional reported features, whereas the other
Table 1. List of all identiﬁed genetic variations in KCNC3.
Frequency Amino acid
conservation
Alamut prediction
SNP
number
cDNA
change
Amino
acid
change
Number
of Dutch
cases
Number
of EVS-
EA
alleles
Mammals Kv
isoforms
GVGD SIFT Mutation-
taster
Polyphen2 Splicing
- c.24G>T p.S8 = 1 0 weak no effect
- c.123G>T p.Q41H 5 0 weak benign damaging benign benign no effect
- c.188A>G p.D63G 1 0 weak benign benign benign benign no effect
- c.385G>A p.
D129N
1 0 high moderate benign damaging damaging benign no effect
rs138237939 c.579C>G p.R193
=
2 C = 3/G =
8581
moderate no effect
rs104894699 c.1259G>A p.
R420H
4 0 high high damaging damaging damaging damaging no effect
- c.1268G>A p.
R423H
1 0 high high damaging damaging damaging damaging no effect
- c.1293C>T p.F431
=
1 0 high no effect
rs148033381 c.1429G>A p.
D477N
1 T = 2/C =
8598
high weak benign benign damaging benign no effect
- c.1603G>A p.
V535M
2 0 high high damaging damaging damaging damaging no effect
rs2301357 c.1641G>A p.S547
=
3 T = 34/C
= 8566
high no effect
- c.1771A>G p.
S591G
5 0 moderate moderate benign benign benign benign no effect
- c.1884G>A p.A628
=
1 0 weak no effect
- c.1927G>A p.
G643S
1 0 moderate weak benign benign damaging damaging no effect
- c.1934C>G p.
P645R
1 0 moderate weak benign damaging benign damaging no effect
rs189018316 c.2170
+14C>T
NA 3 A = 84/G
= 8514
NA no effect
- c.2170
+14C>G
NA 1 0 NA no effect
- c.2236G>A p.
D746N
1 0 weak weak benign benign benign damaging no effect
- c.2256G>A p.A752
=
1 0 weak no effect
EVS, Exome Variant Server; EA, European African; GVGD, Grantham variation Grantham Deviation; SIFT, Sorting intolerant from tolerant; NA,
not applicable
doi:10.1371/journal.pone.0116599.t001
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exhibited a slowly progressive spastic ataxic gait and polyneuropathy. Unfortunately, no addi-
tional family members were available for testing. For the remaining two isolated p.S591G pa-
tients, one showed a very mild spastic ataxia syndrome that presented around age 50 years, and
the other suffered from slowly progressive cerebellar ataxia with intention tremor and poly-
neuropathy at age 50 years. The p.D129N case was diagnosed at age 20 years, with severe cere-
bellar ataxia, dysarthria and intellectual disability, with a rapid progression after 25 years of
age. Detailed clinical information was not available for the other cases.
The synonymous variants p.S8 = , p.F431 = and p.A752 = , and the non-coding c.2170
+14C>G variant did not affect potential splice sites, whereas p.A628 = was predicted to poten-
tially activate a cryptic splice site. However, an in vitro splicing assay did not show any defect
(data not shown).
Functional assessment of the novel KCNC3 variations on Kv3.3 channel
trafficking and function
Alamut predicted p.V535M to be the only pathogenic mutation and gave inconclusive results
or benign outcome on the other missense variants, but because of the reporting of functional
proof of p.F448L being pathogenic whilst the prediction was benign, we decided to further ana-
lyze all these novel KCNC3 variants for Kv3.3’s protein subcellular localization (including
p.R420H and p.R423H) and function.
First, we characterized the trafficking properties of the various Kv3.3 channels in transiently
transfected HeLa cells by immunocytochemistry (Fig. 1A). Wild type (WT) Kv3.3 and channels
carrying the p.D129N, p.D477N, p.V535M, p.S591G, p.G643S, p.P645R and p.D746N variants
were located partially at the plasma membrane and exhibited different degrees of co-localization
with the specific markers for endoplasmatic reticulum (ER) and Golgi apparatus (GA), Cal-
nexin and Golgin-97, respectively (Fig. 2A). In contrast, the p.R420H and p.R423H mutant
Kv3.3 channels showed ER retention, as described previously [17,30].
Secondly, we investigated whether the novel variants would affect the functional properties
of the Kv3.3 channel. Whole-cell patch-clamp experiments were performed in CHO-K1 cells
expressing either WT or Kv3.3 carrying the various novel variants (Fig. 2). We confirmed sig-
nificant loss of Kv3.3 channel activity due to the p.R420H and p.R423H mutations and a shift
in activation curve towards the hyperpolarized direction for p.F448L mutant Kv3.3 (data not
shown), as previously described [2,6,16]. We observed that only the Kv3.3 channel carrying the
p.S591G variant exhibited a significantly reduced channel activity compared with WT Kv3.3
(22.2% loss at +70 mV) (Fig. 1A, Table 2); this was not observed for any of the other variants.
To characterize the steady-state of activation, normalized conductance values were plotted ver-
sus voltage (Fig. 2B). Here, the p.D129N and p.V535M variants shifted the voltage dependence of
activation (V1/2 act) to more hyperpolarized voltages by-6 mV and-28 mV, respectively, with no
changes in the slope factor (Fig. 2B, Table 2). In contrast, p.S591G variant shifted the V1/2 act to
more depolarized voltages by +16 mV, with a slightly reduction of the slope factor. The remaining
variants did not significantly alter the channel activation properties of Kv3.3 (Table 2).
We observed a slow and variable rate of Kv3.3 channel inactivation in CHO-K1 cells (see in-
sert in Fig. 2A). We were therefore unable to assess any significant difference in inactivation be-
tween the WT and the mutant channels.
Discussion
In this study, we screened a total of 848 Dutch cerebellar ataxia patients for mutations in
KCNC3, in order to identify novel SCA13 pathogenic mutations, to gain insights into their
mode of pathogenesis, and to establish a crude estimate of SCA13 disease prevalence in the
KCNC3Mutational Spectrum in Dutch Ataxia Cases
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Dutch ataxia population. We combined in silico prediction, co-segregation analysis (when pos-
sible), and functional analysis. Using this strategy, we identified at least one novel missense
mutation in KCNC3 that causes SCA13: p.V535M, as well as the previously reported p.R420H
and p.R423H. Additionally, p.D129N and p.S591G might be novel SCA13 mutations as well
but could still be rare benign variants. These three or five mutations were identified in five or
eleven independently referred index cases, yielding a disease prevalence of SCA13 of
~ 0.6–1.3% (5 or 11/848) in the Netherlands. This makes SCA13 one of the rarer SCA types in
Fig 1. Subcellular localization and trafficking of Kv3.3WT andmutants.Confocal images showing HeLa
cells expressing EGFP-Kv4.3 WT or carrying the genetic variants (green) stained with anti-Calnexin
(endoplasmic reticulum) and anti-Golgin97 (Golgi apparatus) (red), and Dapi (nucleus; blue). Scale bar, 25
μm.
doi:10.1371/journal.pone.0116599.g001
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the Netherlands. If we imply that the p.S591G is a mutation, and these five p.S591G cases are
in fact (distantly) related a founder effect would even lower the SCA13 disease prevalence.
Due to the limitations of in silico prediction programs and the lack of additional family
members to test for co-segregation, functional studies are needed to establish the pathogenicity
of identified variants. All discussed variants change amino acids that are 100% conserved
across the phyla (p.D129, located in the N-terminal cytoplasmatic tail; and p.V535, located in
the S6 domain), or that are conserved throughout mammals (p.S591, in the initial part of the
C-terminal cytoplasmatic tail), or that are fully conserved among other members of the human
Kv3 family (p.V535 and p.S591) (S1 Fig.). These amino acids apparently play a crucial role in
Kv3.3 channel functioning, as shown in our functional assays. Additionally, p.D129 is
Fig 2. D129N, V535M and S591G variants affect the functional channel properties of Kv3.3. A)
Potassium currents recorded from CHO-K1 cells expressing Kv3.3 WT or mutants. Graph shows current
amplitudes evoked by pulsing from-70 mV to +70 mV in 10 mV increments and plotted versus voltage for WT
(black), D129N (violet), D477N (pink), V535M (red), S591G (green), G643S (light blue), P645R (dark blue),
D746N (yellow) and control untransfected cells (grey). Data are provided as mean ± SEM, n = 10. Inset:
Representative current traces obtained at +70 mV scaled and overlaid for Kv3.3WT and mutants. B)
Normalized conductance values were plotted versus voltage and are shown as mean ± SEM. Data were fitted
with a Boltzmann function to obtain the V1/2 of activation and the slope factor (Table 2).
doi:10.1371/journal.pone.0116599.g002
Table 2. Overview of Kv3.3 channel properties.
Current density +70 mV(pA) n = 10 V1/2 Activation (mV) Slope (mV)
WT Kv3.3 9711 ± 453 1.46 ± 2.2 (10) 15.5 ± 1
p.D129N 10588 ± 528 -7.79 ± 2.4* (14) 13.4 ± 1.3
p.D477N 10583 ± 371 0.79 ± 3 (10) 13,5 ± 0.9
p.V535M 10417 ± 589 -29.6 ± 1.0**** (18) 18.2 ± 0.8*
p.S591G 7661 ± 223** 17.8 ± 3.1* (16) 12.8 ± 1.2*
p.G643S 10736 ± 468 -4.9 ± 2.8 (10) 15.6 ± 1.5
p.P645R 8986 ± 733 -4.26 ± 2.3 (10) 15.9 ± 1.1
p.D746N 10551 ± 538 3.3 ± 1.0 (10) 13.7 ± 0.4
Statistical analysis t-test:
* p<0.05;
** p<0.001;
*** p<0.0001;
**** p<0.00001.
Values are provided as mean ± SEM (n).
doi:10.1371/journal.pone.0116599.t002
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conserved in family member Kv3.1, which is predicted to assemble with Kv3.3 to form hetero-
tetramer channels [17]. Similarly, our functional work showed that those variants, which were
moderately or weakly conserved and predicted to be benign by more than two programs in
Alamut, exhibited normal Kv3.3 channel function.
Previous studies suggested a correlation between the clinical phenotype and the respective
genotypes, through the differential effects of the mutations on Kv3.3 channel function, as was
determined by electrophysiological experiments in oocytes [2,6,16,17]. Altered channel gating
(hyperpolarized shift in activation) was observed for both p.R423H and p.F448L mutant Kv3.3
and correlated strongly with an early disease onset, whereas suppression of Kv3.3 channel ac-
tivity caused by p.R420H corresponded with a late age-of-onset. How the trafficking deficits of
both p.R420H and p.R423H mutant Kv3.3 channels observed in cell models [17,30] contribute
to the disease phenotype remains to be elucidated. Our results support this phenotype-
genotype correlation, as p.V535Mmutant Kv3.3 channels also exhibited a shift in activation to-
wards more hyperpolarized voltages that correlated with infant/young-onset of the disease. Ad-
ditionally, all patients carrying the p.R423H and p.V535M mutations exhibited mild
intellectual disability as a common feature. Notably, the p.D129N variant was also associated
with a hyperpolarized shift in channel activation and young age of onset. In contrast, reduced
Kv3.3 channel activity and a depolarized shift in activation caused by p.S591G was associated
with a spastic ataxic gait in all cases. This suggests that the presence and/or the direction of the
shift in the voltage-dependent activation may be a crucial component in determining the age of
onset and nature of the clinical symptoms of SCA13. However, this correlation is not always
easy to establish and may not hold for other ataxias caused by mutations in voltage-gated po-
tassium channels, including SCA19 and episodic ataxia type 1 [29,31].
Given previous work that showed that p.R420H, p.R423H, and p.F448L mutant subunits ex-
hibited a dominant effect on wild type Kv3.3 channel activity and gating [2,6,16,20], we hy-
pothesize that the p.V535M mutant subunits may also dominantly affect wild type Kv3.3
function, but this prediction warrants further functional studies. Additionally, we need to col-
lect more family members of the cases carrying the p.D129N and p.S391G variants to fully con-
firm their pathogeneity.
Although we demonstrated that many Kv3.3 variants do not alter the channel function or
the cellular localization in HeLa or CHO-K1 cells, most of them are located in the C-terminus
of the protein. Since the C-terminal domain seems to target Kv3.3 channels to the distal den-
drites of pyramidal neurons [32], we cannot exclude the possibility that one or more other
C-terminally located variants may alter the subcellular localization in neurons and consequent-
ly cause neuronal dysfunction and SCA13.
In conclusion, SCA13 is a rare SCA genotype in the Netherlands. Our strategy in two large
patient cohorts have identified at least one novel SCA13 mutation, p.V535M, and two potential
additional ones; p.D129N and p.S391G. We have also provided more insight into the existing
genotype-phenotype correlations through the effects of the mutation and variations on channel
gating and function. Furthermore, we propose that intellectual disability and spastic ataxic syn-
drome are part of the clinical spectrum of SCA13. The upcoming introduction of targeted rese-
quencing of all SCA genes (rare and more common types) in routine diagnostics will
undoubtedly lead to the identification of many more variants of unknown clinical significance.
For these variants, functional studies will be of the utmost importance.
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